ARCT Q1 2024 Earnings — Arcturus Therapeutics Holdings Inc. Revenue & Financial Results | Market Cap Arena

ARCTArcturus Therapeutics Holdings Inc.

$217M

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$33M-59.4% YoY

Gross Profit

$33M100.0% margin

Operating Income

-$30M-93.3% margin

Net Income

-$27M-82.3% margin

EPS (Diluted)

$-1.00

QoQ Revenue Growth

+30.0%

Cash Flow

Operating Cash Flow

-$6M

Free Cash Flow

-$6M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$419M

Total Liabilities

$155M

Stockholders' Equity

$264M

Cash & Equivalents

$288M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$33M	$80M	-59.4%
Gross Profit	$33M	$29M	+14.3%
Operating Income	-$30M	$15M	-306.1%
Net Income	-$27M	$51M	-152.8%

Revenue Segments

Collaboration Revenue

$33M86%

Grant

$5M14%